URSODEOXYCHOLIC ACID

Ewing's Family Tumors

Masonic Cancer Center, University of MinnesotaSmall moleculeN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

57 Active assets in the Ewing's Family Tumors cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Milton S. Hershey Medical Center	Phase 3	BB
Nivolumab Children's National Research Institute	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B
Hycamtin Pfizer	Phase 2	B
Inno-206 Children's National Research Institute	Phase 2	B

View all 50 →

Same molecule, other indications

URSODEOXYCHOLIC ACID is also rated in:

primary biliary cholangitisDormant

A

Indicative ·

82 / 100

Nonalcoholic Steatohepatitis (NASH)Dormant

BBB

Indicative ·

74 / 100

cirrhosis of liverDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.